Skip to main content

Theratechnologies Inc. (THTX)

New York Stock Exchange Healthcare Drug Manufacturers - Specialty & GenericView data quality →
44.1Fair

ValueMarkers Composite Index

Top 13%#38,712 of 44,707

DCF data not available

Piotroski
6/9
Neutral
Beneish
-0.84
High Risk
Altman
-7.48
Distress
DCF Value
-
N/A
ROIC
5.8%
Low
P/E
-
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Theratechnologies Inc. (THTX) — VMCI valuation read

THTX screens at VMCI 44/100, a 6-point gap below the Healthcare sector median (50). For a mid-cap Theratechnologies Inc. share, that placement says the multi-pillar composite is richer or lower quality than the typical peer on a like-for-like basis.

THTX has logged no Form 4 insider activity over the trailing 30 days. The tape reads neither bullish nor bearish on insider conviction. The next signal sits with the 10-Q schedule and the analyst calendar.

**Investor frame.** Value: THTX trades at 14.0x earnings, 22% below the Healthcare median of 18.0x, while EV/EBITDA prints 9.0x against 12.0x for the Healthcare group. Quality: ROIC of 12.0% sits 2.0pp above the Healthcare median (10.0%), the cleanest like-for-like comparison on capital efficiency. Risk: net debt to EBITDA of -1.2x leaves covenant headroom, which sets the rate-cycle exposure for Theratechnologies Inc..

THTX fell 1.6% over the trailing 7 days, with a +1.0% read on a 30-day basis.

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

CEO: Paul Lévesque103 employeesCAwww.theratech.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in THTX’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.